Introduction
Immunization is a fundamental part of pediatric healthcare and has
significantly improved standards of international public health.
Previous studies demonstrate intensive chemotherapy may cause notable
decreases in vaccine-specific antibody titers in childhood cancer
survivors (CCS). 1-6
In CCS, the loss of protective antibodies poses a risk from
vaccine-preventable infections well after immune
reconstitution.7 These potentially life-threatening
infections represent an avoidable source of morbidity and mortality and
may create potential disease vectors that threaten public health
initiatives.
While there are published guidelines for the revaccination of
hematopoietic stem cell transplant (HSCT) patients, there are no unified
guidelines for the revaccination of CCS not undergoing
HSCT.8,9 Vaccine-specific titer data for CCS has been
limited to studies with low sample sizes and conflicting
conclusions.10-13 More vaccine-specific titer data is
needed to build standardized guidelines for this vulnerable population.